Drug intelligence / Profile preview

evunzekibart

Development stage: Phase 1
Lead developer: Alligator Bioscience
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Evunzekibart (ATOR-1017) is a human agonistic immunoglobulin G4 (IgG4) monoclonal antibody targeting the costimulatory receptor 4-1BB (CD137). Developed by Alligator Bioscience, it is designed as a second-generation 4-1BB agonist that requires Fc-gamma receptor engagement for its activity, aiming to provide potent T-cell and natural killer (NK) cell activation within the tumor microenvironment while minimizing systemic toxicity and hepatotoxicity. In clinical studies, it has been evaluated as a monotherapy for patients with advanced, unresectable solid tumors who have failed standard-of-care treatments.

Other names: evunzekibart

Targets

TNFRSF9 (CD137 extracellular domain)

Beyond the preview

Go deeper on evunzekibart.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on evunzekibart.

Explore the full profile